Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K)

References

• NilssonBBümmingPMeis-KindblomJMGastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era – a population-based study in western SwedenCancer2005103482182915648083
   PubMed Web of Science ®Google Scholar
• CorlessCLGastrointestinal stromal tumors: what do we know now?Mod Pathol201427Suppl 1S1S1624384849
   PubMed Web of Science ®Google Scholar
• MiettinenMLasotaJGastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular geneticsPol J Pathol200354132412817876
   PubMedGoogle Scholar
• KindblomLGRemottiHEAldenborgFMeis-KindblomJMGastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of CajalAm J Pathol19981525125912699588894
   PubMed Web of Science ®Google Scholar
• WestRBCorlessCLChenXThe novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation statusAm J Pathol2004165110711315215166
   PubMed Web of Science ®Google Scholar
• Debiec-RychterMSciotRLe CesneAEORTC Soft Tissue and Bone Sarcoma GroupItalian Sarcoma GroupAustralasian GastroIntestinal Trials GroupKIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumoursEur J Cancer20064281093110316624552
   PubMed Web of Science ®Google Scholar
• CorlessCLSchroederAGriffithDPDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinibJ Clin Oncol200523235357536415928335
   PubMed Web of Science ®Google Scholar
• HeinrichMCGriffithDJDrukerBJWaitCLOttKAZiglerAJInhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitorBlood200096392593210910906
   PubMed Web of Science ®Google Scholar
• DemetriGDvon MehrenMBlankeCDEfficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumorsN Engl J Med2002347747248012181401
   PubMed Web of Science ®Google Scholar
• von MehrenMHeinrichMCJoensuuHBlankeCDWehrleEDemetriDFollow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT+ gastrointestinal stromal tumors (GIST) [abstract]J Clin Oncol201129Suppl abstr 10016
   Google Scholar
• CorlessCLBallmanKVAntonescuCRPathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trialJ Clin Oncol201432151563157024638003
   PubMed Web of Science ®Google Scholar
• VerweijJCasaliPGZalcbergJProgression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialLancet200436494401127113415451219
   PubMed Web of Science ®Google Scholar
• HeinrichMCCorlessCLDemetriGDKinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumorJ Clin Oncol200321234342434914645423
   PubMed Web of Science ®Google Scholar
• Debiec-RychterMWasagBStulMGastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivityJ Pathol2004202443043815095270
   PubMed Web of Science ®Google Scholar
• Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST)Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patientsJ Clin Oncol20102871247125320124181
   PubMed Web of Science ®Google Scholar
• HeinrichMCOwzarKCorlessCLCorrelation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology GroupJ Clin Oncol200826335360536718955451
   PubMed Web of Science ®Google Scholar
• MirandaCNuciforaMMolinariFKRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumorsClin Cancer Res20121861769177622282465
   PubMed Web of Science ®Google Scholar
• LasotaJCorlessCLHeinrichMCClinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 casesMod Pathol200821447648418246046
   PubMed Web of Science ®Google Scholar
• SubramanianSWestRBCorlessCLGastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profilesOncogene200423477780779015326474
   PubMed Web of Science ®Google Scholar
• WasagBDebiec-RychterMPauwelsPDifferential expression of KIT/PDGFRA mutant isoforms in epithelioid and mixed variants of gastrointestinal stromal tumors depends predominantly on the tumor siteMod Pathol200417888989415154005
   PubMed Web of Science ®Google Scholar
• RossiSGasparottoDToffolattiLMolecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small sizeAm J Surg Pathol201034101480149120861712
   PubMed Web of Science ®Google Scholar
• ArneGKristianssonENermanOExpression profiling of GIST: CD133 is associated with KIT exon 11 mutations, gastric location and poor prognosisInt J Cancer201112951149116121064103
   PubMed Web of Science ®Google Scholar
• KernAGörgensHDittertDDMutational status of KIT and PDGFRA and expression of PDGFRA are not associated with prognosis after curative resection of primary gastrointestinal stromal tumors (GISTs)J Surg Oncol20111041596521387320
   PubMed Web of Science ®Google Scholar
• Calabuig-FariñasSLópez-GuerreroJANavarroSEvaluation of prognostic factors and their capacity to predict biological behavior in gastrointestinal stromal tumorsInt J Surg Pathol201119444846121427092
   PubMed Web of Science ®Google Scholar
• WozniakARutkowskiPPiskorzAPolish Clinical GIST RegistryPrognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experienceAnn Oncol201223235336021527588
   PubMed Web of Science ®Google Scholar
• KangGLeeJJangKTMultiplex mutation screening by mass spectrometry in gastrointestinal stromal tumoursPathology201244546046422777070
   PubMed Web of Science ®Google Scholar
• JoensuuHRutkowskiPNishidaTKIT and PDGFRA mutations and the risk of GI stromal tumor recurrenceJ Clin Oncol201533663464225605837
   PubMed Web of Science ®Google Scholar
• BozziFConcaEManentiGHigh CD133 expression levels in gastrointestinal stromal tumorsCytometry B Clin Cytom201180423824721462307
   PubMed Web of Science ®Google Scholar
• KangHJRyuMHKimKMImatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) studyActa Oncol201251452853622150077
   PubMed Web of Science ®Google Scholar
• LeeJHKimYChoiJWKimYSCorrelation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysisJ Gastrointestin Liver Dis201322441341824369323
   PubMed Web of Science ®Google Scholar
• HeinrichMCCorlessCLBlankeCDMolecular correlates of imatinib resistance in gastrointestinal stromal tumorsJ Clin Oncol200624294764477416954519
   PubMed Web of Science ®Google Scholar
• BednarskiBKAraujoDMYiMAnalysis of prognostic factors impacting oncologic outcomes after neoadjuvant tyrosine kinase inhibitor therapy for gastrointestinal stromal tumorsAnn Surg Oncol20142182499250524639192
   PubMed Web of Science ®Google Scholar
• RevheimMEKristianAMalinenEIntermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816HActa Oncol201352477678223480638
   PubMed Web of Science ®Google Scholar
• IshikawaTNakaiNLiuNNIn vivo effect of imatinib on progression of cecal GIST-like tumors in exon 17-type c-kit knock-in miceLab Invest200989101161116819636292
   PubMed Web of Science ®Google Scholar
• LoughreyMBBeshayVDobrovicAZalcbergJWaringPMPathological response of gastrointestinal stromal tumour to imatinib treatment correlates with tumour KIT mutational status in individual tumour clonesHistopathology20064919910016842259
   PubMed Web of Science ®Google Scholar
• WangCMFuHZhaoGFSecondary resistance to imatinib in patients with gastrointestinal stromal tumors through an acquired KIT exon 17 mutationMol Med Rep20092345546021475850
   PubMed Web of Science ®Google Scholar
• WangCMHuangKZhouYMolecular mechanisms of secondary imatinib resistance in patients with gastrointestinal stromal tumorsJ Cancer Res Clin Oncol201013671065107120043176
   PubMed Web of Science ®Google Scholar
• CameronSSavvoukidisTArmbrustTAnalysis of a case with disappearance of the primary gastrointestinal stromal tumor and progressive liver metastases under long-term treatment with tyrosine kinase inhibitorsMed Oncol201027221321819294538
   PubMed Web of Science ®Google Scholar
• NishidaTTakahashiTNishitaniAJapanese Study Group on GISTSunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT geneInt J Clin Oncol200914214314919390946
   PubMed Web of Science ®Google Scholar
• HansonJATrentJCYangDCooperKSmall-intestinal rhabdoid gastrointestinal stromal tumor (GIST): mutation analysis and clinical implications of a rare morphological variantInt J Surg Pathol201119565365721531698
   PubMed Web of Science ®Google Scholar
• GaoJTianYLiJSunNYuanJShenLSecondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumorsMed Oncol201330252223456621
   PubMed Web of Science ®Google Scholar
• SingeltaryBGhoseASussmanJChoeKOlowokureODurable response with a combination of imatinib and sorafenib in KIT exon 17 mutant gastrointestinal stromal tumorJ Gastrointest Oncol201451E27E2924490049
   PubMedGoogle Scholar
• DemetriGDvan OosteromATGarrettCREfficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trialLancet200636895441329133817046465
   PubMed Web of Science ®Google Scholar
• HeinrichMCMakiRGCorlessCLPrimary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumorJ Clin Oncol200826335352535918955458
   PubMed Web of Science ®Google Scholar
• ReichardtPBlayJYGelderblomHPhase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinibAnn Oncol20122371680168722357255
   PubMed Web of Science ®Google Scholar
• DemetriGDReichardtPKangYKGRID study investigatorsEfficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trialLancet2013381986329530223177515
   PubMed Web of Science ®Google Scholar
• ParkSHRyuMHRyooBYSorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study groupInvest New Drugs20123062377238322270258
   PubMed Web of Science ®Google Scholar
• KindlerHLCampbellNPWroblewskiKSorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): final results of a University of Chicago Phase II Consortium trial [abstract]J Clin Oncol201129Suppl abstr 10009
   Google Scholar
• Debiec-RychterMCoolsJDumezHMechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutantsGastroenterology2005128227027915685537
   PubMed Web of Science ®Google Scholar
• HsuehYSLinCLChiangNJSelecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutationsPLoS One201386e6576223840364
   PubMed Web of Science ®Google Scholar